Ryan Bushey
Digital Editor

Ryan Bushey is a digital editor for Advantage Business Media’s Science Group.  He covers scientific discoveries, emerging technologies and the business of the life sciences sector for R&D Magazine and Drug Discovery & Development along with managing social media for both publications. He’s an experienced journalist whose work has appeared in Business Insider, Slate, and Indiewire.

A new analysis for heart failure drug Entresto revealed novel insights for managing diabetes when compared to an older medication.
Digital Editor
|
3.27.2017
12:54pm
One area targeted for drastic downsizing is agencies performing government-funded science research, including the National Institutes of Health (NIH).
Digital Editor
|
3.22.2017
10:24am
These late-stage study results were presented in Washington D.C. at the annual American College of Cardiology meeting.
Digital Editor
|
3.20.2017
10:28am
An experimental treatment for clostridium dificile infections is getting a second chance.
Digital Editor
|
3.17.2017
8:50am
The project, called the Asthma Mobile Health Study, launched in March 2015.
Digital Editor
|
3.16.2017
9:50am
Advertisement
The financing will help Spero Therapeutics further advance its assets into the different stages of clinical testing.
Digital Editor
|
3.16.2017
9:44am
The company will work with Editas Medicine, a biotech backed by Bill Gates and Google.
Digital Editor
|
3.15.2017
10:45am
The fallout from Mylan’s EpiPen pricing controversy appears to be taking a toll, according to a new analysis.
Digital Editor
|
3.8.2017
8:40am
GlaxoSmithKline could maintain its edge in the respiratory disease treatment space.
Digital Editor
|
3.7.2017
8:29am
Eli Lilly’s grip on the psoriasis treatment space could be getting stronger.
Digital Editor
|
3.6.2017
8:56am
Detailed information regarding these trials were presented at the annual American Academy of Dermatology Meeting in Orlando, Florida.
Digital Editor
|
3.6.2017
8:36am
Researchers are moving closer to refining a novel gene therapy for slow heartbeats.
Digital Editor
|
3.1.2017
9:00am
Johnson & Johnson plans on releasing annual reports containing this information going forward.
Digital Editor
|
3.1.2017
8:58am
Advertisement
Pfizer is getting closer to gaining regulatory approval for an investigational leukemia treatment called inotuzumab ozogamicin.
Digital Editor
|
2.22.2017
8:31am
British-based pharmaceutical firm AstraZeneca may be gaining an advantage in the burgeoning PARP inhibitor drug space.
Digital Editor
|
2.21.2017
8:19am
Boston-based Rhythm Pharmaceuticals obtained a new round of funding to help continue development of its lead peptide therapy setmelanotide.
Digital Editor
|
2.17.2017
8:40am
A promising multiple sclerosis treatment called Ocrevus will play a crucial role in this growth.
Digital Editor
|
2.16.2017
8:23am
Investigators will gain a five-year appointment and up to $1.5 million in funding to kick start their research projects.
Digital Editor
|
2.15.2017
8:41am
Another drug company reignited the debate over appropriate pricing policies for important medications.
Digital Editor
|
2.14.2017
9:06am
More than 150 biotech CEOS, venture capitalists and startup founders signed a letter to the President expressing their deep concern and opposition to the order.
Digital Editor
|
2.9.2017
7:59am
British-based GW Pharmaceuticals received more good news regarding its cannabis-based drug development efforts.
Digital Editor
|
2.8.2017
8:20am
Advertisement
Investigators running this randomized, double-blind, placebo-controlled trial recruited 150 elderly patients diagnosed with acute myeloid leukemia.
Digital Editor
|
2.6.2017
1:02pm
Bristol-Myers Squibb’s prized immuno-oncology drug gained another label expansion.
Digital Editor
|
2.3.2017
9:42am
Another drug company unveiled a new strategy for dealing with the drug pricing debate.
Digital Editor
|
2.2.2017
9:28am
The government is working on new strategies to ensure pharmaceutical and biotech R&D can thrive in the country after the process is completed.
Digital Editor
|
1.27.2017
9:04am
The lobbying group began laying the groundwork for this program several months ago in the midst of the election.
Digital Editor
|
1.26.2017
10:22am
Celgene expanded its autoimmune disease pipeline with a new acquisition.
Digital Editor
|
1.26.2017
10:20am
MDX has traversed a difficult path during the research and development process.
Digital Editor
|
1.18.2017
7:42am
President-elect Donald Trump went after the pharmaceutical industry in the opening remarks of his first press conference since the election.
Digital Editor
|
1.12.2017
8:32am
The Cambridge, Massachusetts-based biotech company has kept its pipeline a secret until now.
Digital Editor
|
1.11.2017
9:52am
Japanese drugmaker Takeda acquired Boston-based Ariad Pharmaceuticals, a biotech company specializing in cancer drugs.
Digital Editor
|
1.10.2017
8:34am
The biotech startup wants to use this new funding to advance development of its specialized early detection cancer test.
Digital Editor
|
1.9.2017
8:29am
The Foster City, California-based biotech added a top cancer specialist to its executive ranks.
Digital Editor
|
1.5.2017
8:35am
An analysis published by Deloitte’s Centre for Health Solutions indicated the pharmaceutical industry experienced a continued decline in R&D returns for...
Digital Editor
|
1.3.2017
8:37am
Other researchers have used similar methods to sift through large amounts of data in order to pinpoint promising compounds to treat diseases.
Digital Editor
|
12.30.2016
11:08am
These articles provide a snapshot of the change the pharmaceutical industry experienced throughout the year.
Digital Editor
|
12.21.2016
8:30am
A new report explains how hospitals are implementing aggressive new measures to cut pharmaceutical spending in the face of rapidly rising prices for certain...
Digital Editor
|
12.20.2016
8:29am
Novartis is bolstering its dermatology portfolio with a new acquisition.
Digital Editor
|
12.19.2016
8:18am
Voyager Therapeutics is testing an experimental gene therapy that could boost Parkinson’s patients’ responses to levodopa.
Digital Editor
|
12.15.2016
9:00am